<DOC>
	<DOCNO>NCT01043146</DOCNO>
	<brief_summary>Primary Trial objective : To evaluate pharmacokinetics -dynamics five strength COR-1 ( 10 , 40 , 80 , 160 , 240 mg ) 50 healthy , male volunteer single intravenous administration ( 8 subject verum per dose level , 10 subject receive placebo ) Secondary objective : To evaluate safety tolerability use adverse event ( AEs ) vital sign</brief_summary>
	<brief_title>Safety , Pharmacokinetic Pharmacodynamic Study COR-1 , Anti-ß1 Receptor Antibody Cyclopeptide</brief_title>
	<detailed_description>Primary Trial objective : To evaluate pharmacokinetics -dynamics five strength COR-1 ( 10 , 40 , 80 , 160 , 240 mg ) healthy , male volunteer single intravenous administration Secondary objective : To evaluate safety tolerability use adverse event ( AEs ) , vital sign include blood pressure/pulse rate ( BP/PR ) , electrocardiographic examination ( 12 lead ECG ) , evaluation antibody titer safety laboratory test ( biochemistry , hematology , coagulation , urinalysis ) Methodology : Mono-center , single-blind , dose escalate study five dose level ( 8 subject verum per dose level , 2 subject receive placebo ) total 50 volunteer .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Healthy , male Caucasians 18 45 year age , inclusive Normotensive subject ( systolic BP &lt; 140 mmHg diastolic BP &lt; 90 mmHg ) Body mass index ( BMI ) 1927 , minimal weight 60 kg Negative result HIV antibody , HBs antigen ( HBsAg ) HCV test , negative result antiß1receptorautoantibody screening Signed Informed Consent Form Normal clinically irrelevant laboratory finding Autoimmune disorder Kidney diseases Liver disease , liver function impairment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>anti-beta1 adrenergic receptor</keyword>
	<keyword>autoantibody</keyword>
	<keyword>cyclic peptide</keyword>
	<keyword>heart failure</keyword>
</DOC>